ABSTRACT
Background Alpha globin gene (HBA) copy number is variable among people of African descent. HBA limits endothelial nitric oxide signaling and variation in gene copy number could modify kidney disease risk in this population.
Objective To examine the association of HBA copy number with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). We hypothesized that higher HBA copy number would be associated with greater CKD prevalence and ESKD incidence.
Design Prospective, longitudinal cohort from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study which enrolled participants from 2003 through 2007 and conducted follow-up through June 2014. Data were analyzed from January 2018 through January 2021.
Setting Community-dwelling participants enrolled throughout the contiguous United States
Participants Black Americans age 45 years and older
Measurements HBA copy number was measured using droplet-digital PCR on genomic DNA; copy number ranged from 2 to ≥ 5 copies. The prevalence ratio (PR) of CKD and relative risk (RR) of incident reduced estimated glomerular filtration rate (eGFR) were calculated using modified Poisson multivariable regression employing a log-linear effect of HBA allele count. The hazard ratio (HR) of incident ESKD was calculated using Cox proportional hazards multivariable regression.
Results Among 9,918 participants, HBA gene copy number frequencies were 4%, 28%, 67%, and 1% for 2, 3, 4, and ≥5 copies, respectively. After adjusting for demographic, clinical, and genetic risk factors, each additional copy of HBA was associated with 14% greater prevalence of CKD (PR = 1.14, 95% CI 1.07 to 1.21; P < 0.0001). While there was no significant association with incident reduced eGFR (RR = 1.06, 95% CI 0.94 to 1.18; p = 0.36), the hazard of incident ESKD was 28% higher for each additional copy of HBA (HR = 1.28, 95% CI 1.01 to 1.61; P = 0.04).
Limitations This study did not identify the mechanism by which HBA copy number modifies kidney disease risk. This study focused on Black Americans, a population with a high frequency of the 3.7 kb gene deletion; it is unknown whether HBA modifies kidney disease risk in other populations with the 3.7 kb deletion.
Conclusions Increasing HBA copy number was associated with greater prevalent CKD and incident ESKD in a national longitudinal study of Black Americans.
Funding Source National Institutes of Health
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding Source: National Institutes of Health
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided oral and written informed consent. The Institutional Review Board of the University of Alabama at Birmingham, the lead study center, approved this study. In addition, the REGARDS study was approved by participating center Institutional Review Boards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is maintained by the UAB REGARDS Statistical and Data Coordinating Center (SDCC).
